- ReShape Lifesciences (OTC:RSLS) Q3 results ($M): Revenue: 0.4 (-2.7%); net loss: (7.0) (+30.0%); cash and equivalents: 0.5 (-95.1%).
- European study initiated in Europe to support CE Mark certification of ReShape Vest.
- Retired all Series D convertible preferred shares.
- Shares are up 4% after hours.
- Previously: ReShape Lifesciences EPS of -$27.46 (Nov. 14)
ReShape Q3 top line down 3%; shares up 4% after hours
Recommended For You
More Trending News
About RSLS Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
RSLS | - | - |
ReShape Lifesciences Inc. |